ReviewCureus2025
Use of Fructosamine for Glycemic Monitoring in Patients With Sickle Cell Disease and Diabetes: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease is characterized by various forms of hemoglobin that interfere with hemoglobin A1c (HbA1c) testing, which is commonly used to diagnose and monitor diabetes. This interference puts patients with sickle cell disease at risk of inaccurate monitoring and misdiagnosis due to improperly planned HbA1c testing. Despite awareness of these issues, there is still disagreement regarding the most appropriate method of measuring HbA1c in patients with sickle cell disease, along with a lack of clear guidance on using fructosamine as an alternative marker in patients with diabetes and sickle cell disease. We employed a systematic review technique to assess the efficacy of fructosamine in diagnosing and monitoring diabetes in patients with sickle cell disease. The study showed that fructosamine is highly associated with fasting blood glucose levels in patients with sickle cell trait, and even more so in those with sickle cell disease and poorly controlled diabetes. It also demonstrated a fair association with HbA1c, as measured by some of the recommended instruments for use in patients with sickle cell disease. These results suggest that fructosamine can play a valuable role in managing diabetes in patients with sickle cell trait and disease, along with HbA1c, as HbA1c is widely used to monitor diabetes, even in patients with diseases that might affect the accuracy of HbA1c measurement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.